antibody drug conjugate

FDA grants breakthrough status to T-DXd for two HER2-positive cancers

Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...